Bio-Rad Laboratories, Inc. (BIO)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $385.12
- As of
Kresmion compiles this page from BIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BIO-RAD LABORATORIES, INC. (BIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
See the full BIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BIO on one page. Preview it with sample data, then open it live with a free account.
Preview the BIO dossierActive events for BIO
- high13F: funds added
3 tracked funds increased BIO this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +1411% to BIO (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +7387% to BIO (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +136% to BIO (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 48.4%, EPS $2.62 vs $1.7652 estimate
FREE, NO ACCOUNT
Every event on BIO, as it fires
You are seeing 5 of 9 events recorded on BIO since 2026-06-10.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 090572207 · 2026Q2 | $17.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 090572207 · 2026Q2 | $17.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 090572207 · 2026Q2 | $5.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 090572207 · 2026Q2 | $3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BIO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
BIO against its peers
BIO's operating margin of 1.8% ranks in the 64th percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | BIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.6B USD | 370M USD | 83 | 19 |
| Gross margin | 51.9% | 67.4% | 33 | 19 |
| Operating margin | 1.8% | -6.1% | 64 | 20 |
| Net margin | 29.4% | -8.2% | 98 | 20 |
| Return on equity | 10.2% | -10.0% | 79 | 20 |
| P / E | 13.8x | 32.7x | 8 | 5 |
Peers (20): GMED, SNN, PHG, AXGN, NEOG, UFPT, BFLY, ESTA, ENOV, AVNS.D, AORT, CBLL, BBNX, SIBN, QDEL, IART, INMD, KIDS, TCMD, DCTH. Left out: ALMR (no annual filing), SMMNY (no annual filing), OSSUY (no annual filing), NHNKF (no annual filing), LMRI (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (BIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.